Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018

Gesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH)0 个研究点目标入组 150 人开始时间: 2020年3月17日最近更新: 2021年11月15日

试验速览

暂无简介。

•Myeloid Leukemia (ML) or Myelodysplastic Syndrome (MDS), according to WHO
•Trisomy 21: Down syndrome or mosaic
•Age: > 6 months and = 4 years of age with/without GATA1 mutation OR > 4 years of age < 6 years of age with GATA1 mutation
•Morphology/Immunophenotyping: FAB M0, M6 or M7
•Lansky performance score at least equal to 50; or Karnofsky performance status at least equal to 50, whichever is applicable
•Understand and voluntarily provide written permission of parental/legal representative(s) to the ICF prior to conducting any study related assessments/procedures, also concerning data and tumor material transfer according to ICH/GCP and national/local regulations
•Able to adhere to the study visit schedule and other protocol requirements
•Acceptance that vaccination with live vaccines is not possible while participating in the trial
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 150
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Children with Transient Abnormal Myelopoiesis (TAM), according to WHO
•Cytogenetics: AML with recurrent genetic abnormalities (WHO 2016)
•Previous allogeneic bone marrow, stem cell or organ transplantation
•Evidence of invasive fungal infection or other severe systemic infection requiring treatment doses of systemic/parenteral therapy including known active viral infection with human immunodeficiency virus (HIV) or Hepatitis Type B and C
•Symptomatic cardiac disorders (CTCAE 4.0 Grade 3 or 4)
•Diagnosed Wilson’s Disease
•Major surgery within 21 days of the first dose.
•Any anti-cancer therapy (e.g., intensive chemotherapy, biologics or radiotherapy) for more than 14 days or within 4 weeks before start of therapy, except low-dose cytarabine for the treatment of TAM.
•Concomitant treatment with any other anticancer therapy except those specified in protocol during the study therapy
•Treated by any investigational agent in a clinical study within previous 4 weeks
•History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
•Former Enrolment to this study
•The patient concerned has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities

发起方

Gesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH)